Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider Christopher Bowden sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $77.65, for a total value of $155,300.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Christopher Bowden also recently made the following trade(s):
- On Thursday, February 1st, Christopher Bowden sold 2,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $78.75, for a total value of $157,500.00.
Agios Pharmaceuticals Inc (AGIO) opened at $81.81 on Friday. Agios Pharmaceuticals Inc has a one year low of $45.11 and a one year high of $83.92. The company has a market capitalization of $4,690.00, a P/E ratio of -12.14 and a beta of 2.12.
Several brokerages have recently commented on AGIO. SunTrust Banks reiterated a “buy” rating and set a $101.00 target price (up from $80.00) on shares of Agios Pharmaceuticals in a research note on Thursday, February 15th. Credit Suisse Group lifted their target price on Agios Pharmaceuticals from $66.00 to $80.00 and gave the stock an “outperform” rating in a research note on Thursday, February 15th. They noted that the move was a valuation call. JPMorgan Chase & Co. lifted their target price on Agios Pharmaceuticals from $76.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. UBS Group downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 14th. Finally, Needham & Company LLC lifted their target price on Agios Pharmaceuticals from $72.00 to $86.00 and gave the stock a “buy” rating in a research note on Thursday, February 15th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Agios Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $85.50.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Agios Pharmaceuticals by 41.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 762 shares during the period. QS Investors LLC bought a new stake in Agios Pharmaceuticals in the 2nd quarter valued at $144,000. State of Alaska Department of Revenue bought a new stake in Agios Pharmaceuticals in the 4th quarter valued at $160,000. Teacher Retirement System of Texas bought a new stake in Agios Pharmaceuticals in the 3rd quarter valued at $225,000. Finally, S&CO Inc. bought a new stake in Agios Pharmaceuticals in the 3rd quarter valued at $227,000. Institutional investors and hedge funds own 84.04% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Agios Pharmaceuticals Inc (AGIO) Insider Sells $155,300.00 in Stock” was first posted by BBNS and is owned by of BBNS. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://baseballnewssource.com/markets/agios-pharmaceuticals-inc-agio-insider-sells-155300-00-in-stock/1908514.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.